23
2024
-
05
Gene testing for keratoconus
Project Introduction
Keratoconus is a type of eye disease characterized by central or paracentral dilation and thinning of the cornea, which protrudes forward in a conical shape. It often causes highly irregular astigmatism and significant decline in late stage vision, leading to blindness; Some patients may experience acute corneal edema, which may leave scars after the edema subsides. This disease occurs more frequently during adolescence and progresses progressively. It is one of the important blinding eye diseases in China.
Detection range
Based on the cutting-edge research results in the field, 31 highly recognized pathogenic gene mutation sites (6 genes) and 12 susceptible risk sites (10 genes) related to keratoconus were screened, comprehensively covering the key genes related to keratoconus currently discovered in the research field, such as VSX1, ZNF469, TUBA3D, etc.
Intended for
Clinical suspicion of keratoconus;
Have a family history of keratoconus;
Preoperative examination for corneal refractive surgery.
Patient benefits
Early diagnosis ：
Latent and early stage patients cannot be diagnosed by routine clinical testing, while genetic testing can effectively detect keratoconus caused by genetic factors in these two stages.
Early diagnosis can be effectively treated through corneal collagen cross-linking surgery, while in late stages, only corneal transplantation can be performed.
Disease prevention ：
For individuals with a family history or suspected of carrying related gene mutations, assessing the risk of disease through testing provides a basis for disease prevention.
Risk assessment ：
Preoperative examination of corneal refractive surgery can improve the detection rate of keratoconus and avoid serious adverse consequences after surgery.
Disease treatment：
Distinguish the causes of keratoconus and develop different treatment plans for keratoconus caused by genetic and non genetic factors.
Project advantages
Expert
Specially designed for keratoconus
Whole
Covering currently recognized genes related to keratoconus
Fast
Short detection cycle, report can be issued within 2 working days
Project Process
Contact us
Consultation on testing projects
Manager Ren +86-15383955001
Customer service
Hot News
undefined
CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.
HUATAO GROUP
Contact us
Telephone:400-6006223 010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing
WeChat subscription account
